Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2009 - 2023)

Teva Pharmaceutical Industries (TEVA) has reported Short-Term Debt issuances for 14 consecutive years, with $700.0 million the latest figure, recorded in Q3 2023.

• Quarterly Short-Term Debt issuances changed N/A year-over-year to $700.0 million in Q3 2023, while the trailing twelve-month figure through Dec 2024 was $700.0 million (down 22.22% YoY) and the FY2023 annual result came in at $700.0 million, changed N/A from the prior year.
• Short-Term Debt issuances rose to $700.0 million in Q3 2023 per TEVA's latest filing, from $200.0 million in the prior quarter.
• Over the last five years, Short-Term Debt issuances for TEVA reached as high as $700.0 million in Q3 2023 and fell as low as -$1.0 million in Q1 2019.
• A 4-year average of $247.1 million and a median of $200.0 million in 2021 frame the typical range for Short-Term Debt issuances.
• Annual changes were most pronounced in 2019 — Short-Term Debt issuances jumped 9900.0% — and 2021, when it slumped 39.02%.
• Year by year, Short-Term Debt issuances stood at $406.0 million in 2019, then retreated by 19.21% to $328.0 million in 2020, then sank by 39.02% to $200.0 million in 2021, then jumped by 250.0% to $700.0 million in 2023.
• According to Business Quant data, Short-Term Debt issuances over the past three periods registered $700.0 million, $200.0 million, and $328.0 million for Q3 2023, Q4 2021, and Q4 2020 respectively.